MHA support leader in pharmaceutical commercialisation services on acquisition of Decisive Consulting
July 8th 2025
Herspiegel, a leader in pharmaceutical commercialisation services has acquired Decisive Consulting.
The strategic expansion unites Decisive Consulting’s global market access focused “Rebel Thinking” with Herspiegel’s world-class commercialisation services to create a powerhouse of strategy, evidence and execution across the product lifecycle.
MHA provided financial and tax due diligence for Herspiegel, which will allow the company to further strengthen their ability to unlock asset value and improve patient access to life-changing therapies. Their integrated approach with Decisive Consulting will bring together scientific insight, evidence strategy, deep market intuition and executional precision.
"It was a pleasure to advise the team at Herspiegel on their acquisition of Decisive Consulting Ltd. The deal will further enhance the firm's position and its ability to maximise asset value while expanding patient access to life-changing therapies. We are excited to see what’s next for Herspiegel and wish them all the best."
Renowned for its bold and inventive approach to problem-solving, Decisive Consulting empowers life sciences companies to defy convention and unlock transformative market access. Now strengthened by the recent acquisitions of FIECON, experts in HEOR and HTA and Herspiegel, with its proven track record in U.S. market access and commercialisation, the expanded team offers a comprehensive suite of services
